Your session is about to expire
← Back to Search
CM24 + Nivolumab for Solid Tumors
Study Summary
This trial is testing a new cancer drug (CM-24) in combination with another drug (nivolumab) to see if it is safe and works well against advanced solid tumors, non-small cell lung cancer, and pancreatic cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a recent biopsy after my last cancer treatment.I have at least one tumor that can be measured and has grown since my last cancer treatment.My cancer is advanced pancreatic cancer, confirmed by tests.My cancer has returned or spread, and I've had 1-2 treatments but they didn't work or caused side effects.I had side effects from previous immunotherapy targeting PD-1/PD-L1.My cancer has worsened after 1 treatment for advanced disease.My immune system is very weak.I have had more than two treatments for my cancer after it spread.I am currently being treated for another cancer.There is a tissue sample from your tumor available from before your first treatment.I have no severe side effects from previous cancer treatments.I have not had major surgery in the last 4 weeks.I have not received a live vaccine in the last 30 days.My brain cancer has not changed recently.I am not pregnant and agree to use birth control or abstain from sex.I have brain metastases that haven't been treated.I have lost more than 10% of my weight in the last 2 months.I do not have serious health issues like heart disease, severe lung problems, or active infections.I am fully active or can carry out light work.Your recent lab test results show that you are healthy enough to participate.
- Group 1: Part D- Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine
- Group 2: Part D- Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV
- Group 3: Part A- Dose escalation of CM24 in combination with nivolumab
- Group 4: Part C- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine
- Group 5: Part C- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV
- Group 6: Part D- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine
- Group 7: Part D- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what medical purposes are CM-24 and Nivolumab - Dose Escalation typically used?
"Traditionally, CM-24 and Nivolumab - Dose Escalation have been prescribed to treat unresectable melanoma. Nonetheless, this therapy has become increasingly popular for individuals with squamous cell carcinoma as well as those at a greater risk of recurrence or disease progression."
Are there any previous investigations that have explored the efficacy of combining CM-24 and Nivolumab in increasing doses?
"Currently, there are 1,504 active clinical trials exploring CM-24 and Nivolumab - Dose Escalation. Of these studies, 298 are in Phase 3. Shanghai is one of the 77,770 locales where research into CM-24 and Nivolumab - Dose Escalation is being conducted."
How many individuals can participate in this research project?
"This study requires 80 participants that satisfy the listed inclusion criteria. The HonorHealth Research Institute in Scottsdale, Arizona and Yale University in New Haven, Connecticut are two of many possible locations for potential enrollees."
Are there a multitude of locations in Canada that are conducting this experiment?
"Patients can participate in this clinical trial at HonorHealth Research Institute, located in Scottsdale Arizona; Yale University situated in New Haven, Connecticut; and The University of Texas M.D. Anderson Cancer Center based out of Houston, Texas along with four additional sites."
Are there available vacancies for participants in this clinical trial?
"Affirmative. According to clinicaltrials.gov, this medical experiment is actively enrolling participants and has been since March 19th 2021; the report was last modified on April 25th 2022."
Share this study with friends
Copy Link
Messenger